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1. Introduction
1.1. ATP-sensitive potassium channels
ATP-sensitive potassium channels (KATP channels) are found in different cell types: in
pancreatic B-cells, in neurons, in heart, in skeletal muscle cells and in smooth vessel muscle
cells (AGUILAR-BRYAN and BRYAN, 1999). In all these cells, KATP channels are important for
coupling the metabolic status to electrical activity (NOMA, 1983; MISLER et al., 1986;
ASHCROFT, 1988). The activity of the channels is reduced by ATP and increased by MgADP.
In pancreatic B-cells, the opening probability of the channels determines the resting
membrane potential. Thus, the channels serve as a link between glucose-induced metabolic
changes and electrical activity and are of central importance for stimulus secretion coupling
(PANTEN et al. 1992; AGUILAR-BRYAN and BRYAN, 1999). In the heart and in neurons, KATP
channels could be involved in regulation of electrical activity in case of ischaemia (GROSS
and AUCHAMPACH, 1992a). In smooth vessel muscle cells they may play a central role in the
regulation of muscle toning (DAVIES et al., 1991).
KATP channels show characteristic pharmacological features. Their opening probability
is reduced by hypoglycemic sulfonylureas (e.g. glibenclamide) and increased by K+ channel
openers (KCOs; e.g. pinacidil) (for example see DÖRSCHNER et al., 1999; GROSS et al., 1999
and UHDE et al., 1999).
1.1.1. KATP channels in pancreatic B-cells
In the resting B-cell (i.e. in the presence of 3 mM of glucose; 37°C) only 6-8% of all KATP
channels are open (PANTEN et al., 1990; SCHWANSTECHER et al., 1992a). The threshold
potential for activation of voltage-dependent Ca2+ channels is reached when less than 3% of
channels are open (COOK et al., 1988; PANTEN et al., 1990; SCHWANSTECHER et al., 1992a).
This degree of channel inhibition is induced by glucose concentrations of more than 6 mM. In
case of glucose concentrations of 6 mM, the insulin-releasing potencies of sulfonylureas lie
within the range of therapeutic plasma concentrations of the free substances and correlate well
with the potencies for KATP channel inhibition (PANTEN et al., 1989). The substrate-induced
inhibition of KATP channels results from a decrease in the ADP concentration and a
simultaneous increase in the ATP concentration at the cytosolic side of the plasma membrane
(ASHCROFT and RORSMAN, 1991).
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1.1.2. KATP channels in neurons
KATP channels with the pharmacological properties of B-cell channels have been identified in
many different neurons: in demyelinised fibres of the sciatic nerve and in the somata of
neurons in hippocampus, neocortex, substantia nigra pars reticulata and caudate nucleus
(JONAS et al., 1991; POLITI and ROGAWSKI, 1991; OHNO-SHOSAKU and YAMAMOTO, 1992;
SCHWANSTECHER and PANTEN, 1994). Under certain conditions, these channels are probably
involved in the regulation of neuronal activity. Thus, their activation in case of hypoxia or
ischaemia presumably leads to a hyperpolarisation of the cells and consequently to an
inhibition of energy consumption and a delay in cell death.
Neuronal KATP channels can be activated by KCOs (SCHMID-ANTOMARCHI et al.,
1990). Sulfonylureas seem to antagonise the protective effect of KATP channel activation and
thereby intensify tissue damage (JIANG et al., 1992; OHNO-SHOSAKU and YAMAMOTO, 1992;
HEURTEAUX et al., 1993). However, therapeutically administered sulfonylureas are unlikely to
pass the intact blood-brain barrier (KELLNER et al., 1969; KOLB et al., 1974; SUGITA et al.,
1982). These substances possibly reach the central nervous system under ischaemic
conditions since prolonged cerebral ischaemia is accompanied by a disturbance of the blood-
brain barrier (KUROIWA et al., 1988; GUMERLOCK, 1989).
1.1.3. KATP channels in heart and skeletal muscle
KATP channels were detected for the first time in cardiac myocytes (NOMA, 1983). High
cytosolic ATP and low cytosolic ADP concentrations may be responsible for the closure of
KATP channels in cardiac muscle under physiological conditions (NICHOLS and LEDERER,
1991). Deficiency of phosphocreatin and consequantively a decrease in cytosolic ATP
concentration during hypoxia or ischaemia may lead, however, to opening of the channels. As
a result, shortening in action potential duration, loss of cellular K+ and accumulation of
extracellular K+ resulting in arrhythmia, were observed (GROSS and AUCHAMPACH, 1992b;
COETZEE, 1992; WILDE and JANSE, 1994). On the other hand, a protective effect results from
shortening of action potential duration since a reduction of Ca2+ influx reduces contractility
and thus energy consumption. Indeed evidence is presented that the opening of cardiac KATP
channels through KCOs such as nicorandil or cromakalim improves oxygen supply, reduces
oxygen consumption in ischaemic areas and has a cardioprotective effect (GROVER, 1994;
AUCHAMPACH et al., 1992 and 1994). Sulfonylureas may, on the other hand, intensify tissue
damage through inhibition of cardiac KATP channels in case of cardiac ischaemia (LYNCH et
al., 1992).
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As in neurons and cardiac muscle the KATP channel in skeletal muscle cells seems to
be closed unless its opening probability is increased by hormones, drugs or a decrease in
energy reserves (DAVIES et al., 1991; LIGHT et al., 1994).
1.1.4. KATP channels in smooth muscle
KATP channels have also been identified in smooth muscle cells of portal vein. The
biophysical properties and the ATP sensitivity of these channels resemble those of the channel
in pancreatic B-cells, (SPRUCE et al., 1985, 1987; KAJIOKA et al., 1991; ASHCROFT and
ASHCROFT, 1990; DAVIES et al., 1991).
The sensitivity of these channels to sulfonylureas however, is lower than that of the B-
cell channel (KOVACS and NELSON, 1991; BEECH et al., 1993; XU and LEE, 1994). In smooth
vessel muscles, KATP channels could be of central importance for the regulation of muscle
toning (DAVIES et al., 1991). It is still unclear whether the channels in smooth muscle cells are
open under physiological conditions.
KCOs relax vascular and non-vascular smooth muscles by opening KATP channels
(HAMILTON, 1986; COOK and QUAST, 1990; BRAY and QUAST, 1992). Due to their
vasodilating properties, these substances lower the blood pressure (EDWARDS and WESTON,
1990; ROBERTSON and STEINBERG, 1990; ANDERSSON and WELSH, 1992).
1.1.5. Structure of KATP channels
KATP channels reconstitute a new class of ion channels. They are assembled with tetradimeric
stoichiometry (SUR/ KIR6.x)4 (Fig.1) from a regulatory sulfonylurea receptor (SUR1 or
SUR2) and a pore-forming inwardly rectifying potassium channel (KIR6.1 or KIR6.2)
(AGUILAR-BRYAN et al., 1995; INAGAKI et al., 1995 and 1996; ISOMOTO et al., 1996;
CLEMENT et al., 1997; YAMADA et al., 1997). SUR1/KIR6.2 reconstitute the
neuronal/pancreatic B-cell KATP channels (INAGAKI et al., 1995), SUR2A/KIR6.2 the cardiac
(INAGAKI et al., 1996; OKUYAMA et al., 1998) and SUR2B/KIR6.1 (or KIR6.2) the vascular
smooth muscle-type KATP channels (ISOMOTO et al., 1996; YAMADA et al., 1997;
SCHWANSTECHER et al., 1998).
The sole expression of KIR6.1 or KIR6.2 does not lead to operative channels (CLEMENT
et al., 1997; GRIBBLE et al., 1997). Since point mutations in KIR6.2 modulate the conductance
of SUR1/ KIR6.2 channels in a characteristic manner (SHYNG et al., 1997), it was concluded
that KIR6.2 or KIR6.1, respectively, represents the pore forming subunit of the channel. This
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conclusion is supported by the fact that carboxyterminal truncation of KIR6.2 results in
formation of a potassium conductance in the absence of SUR (TUCKER et al., 1997).
                                        
Fig. 1 Tetradimeric structure of ATP-sensitive potassium channels (CLEMENT et al., 1997).
The channels consist of four SURx and four KIR6.y subunits.
1.2. Sulfonylurea receptors
A high-affinity binding site for sulfonylureas was detected in membranes from insulin-
secreting cell lines and pancreatic islets (GEISEN et al., 1985; PANTEN et al., 1992;
GOPALKRISHNAN et al., 1993). The good correlation between the KATP channel-blocking and
insulin-releasing potency of sulfonylureas on the one hand, and the affinity of these drugs for
binding to membranes, on the other, suggested that the high-affinity binding site in membrane
preparations represents the sulfonylurea receptor (SCHMID-ANTOMARCHI et al., 1987; GAINES
et al., 1988; PANTEN et al., 1989; SCHWANSTECHER, 1994). High-affinity binding sites for
sulfonylureas were also observed in membranes from brain (KAUBISCH et al., 1982;
ASHCROFT and ASHCROFT, 1992; GOPALKRISHNAN et al., 1993), heart muscle cells (FOSSET et
al., 1988), smooth muscle cells (KOVACS and NELSON, 1991; GOPALKRISHNAN et al., 1993;
ZINI et al., 1991) and skeletal muscle cells (GOPALKRISHNAN et al., 1993).
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1.2.1. Sulfonylurea receptors are ABC- proteins
Sulfonylurea receptors (SURs) are members of the family of ABC-proteins (AGUILAR-BRYAN
et al., 1995; INAGAKI et al., 1996; ISOMOTO et al., 1996). This family probably is the largest
group of proteins for selective transport of substances through biomembranes. The members
of this family have a common organisation with four core domains, two transmembrane
domains and two nucleotide-binding domains, NBF1 and NBF2, (HIGGINS, 1995). The
organisation of an operative transporter is based on two of these basic subunits, i.e. on both
NBFs and two transmembrane domains. In most of the hitherto known procaryotic import
systems, these subunits seem to be expressed as separate polypeptides and are assembled as
hetero- or homodimers into a membrane-bound complex. All bacterial transporters that
mediate solute uptake additionaly require a substrate-binding protein (SBP) located outside
the cytoplasmic membrane. The individual domains may however be fused (partially or
completely) into a single polypeptide and may contain additional regulatory proteins or
transmembrane domains (Fig. 2).
Fig. 2 Domain organization of ABC transporters. A typical ABC transporter consists of four
domains, two highly hydrophobic membrane spanning domains (MD, grey colour) which
form the translocation pathway, and two nucleotide binding folds (NBFs, black colour) which
couple ATP hydrolysis to the transport process. Certain transporters have additional domains
(dotted) that are not part of the core transmembrane translocation mechanism (e.g, CFTR).
The domains are often encoded as separate polypeptides, however, they may also be fused
together in one or several alternative combinations; CFTR = cystic fibrosis transmembrane
conductance regulator, HisQMP2J = histidine permease transporter, Mdr = multi drug
resistance protein, Sap DF = (K+) oligopeptide transporter, Rbs = ribose transpoter, SUR =
sulfonylurea receptor and Fhu C = Fe-ferrichrome transporter. For further details see text.
MD
NBF
SBP Fhu C,B
Rbs A,C
SUR
HisQMP J2
Mdr
CFTR
Sap DF,B,C
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The NBFs contain the characteristic Walker-motifs (WALKER et al.,1982; SARASTE et al.,
1990) as well as an additional highly conserved sequence, the so-called linker region
(SHYAMALA et al., 1991; MIMURA et al., 1991). The Walker A-motif (GX4GKS/T) forms part
of the nucleotide-binding pocket with the highly-conserved lysine (K) residue interacting with
the b- and g- phosphates of ATP (SARASTE et al., 1990; HIGGINS et al., 1992). The Walker B-
motif (R/KX6-8LHyd4D; Hyd = hydrophobic amino acid) is thought to be involved in the
binding of the adenine ring (BEAUDET and GROS, 1995; FRY et al., 1986), while the linker
region (LSGGX3RHydXHydA) probably transduces conformational changes resulting from
ATP hydrolysis to other parts of the protein (SHYAMALA et al., 1991; MIMURA et al., 1991).
A comparison of sequences shows that SUR possesses strong homology to the
"multidrug-related protein" (MRP), the "P-glycoprotein-related" protein of Leishmania and
the "Cystic Fibrosis transmembrane conductance regulator" (CFTR) (AGUILAR-BRYAN et al.,
1995; BRYAN and AGUILAR-BRYAN, 1997). AGUILAR-BRYAN et al. (1995) proposed a
transmembrane topology for SUR1 consisting of nine transmembrane segments before NBF1
and a further four localised between NBF1 and NBF2 at the carboxy-terminal end. In a more
recent study TUSNADY et al. (1997) suggested that SUR1 is formed from eleven
transme mbrane segments before NBF1 and six between NBF1 and the C-terminally localised
NBF2 (Fig. 3).
Fig. 3 Transmembrane topology of SUR1. Model proposed by TUSNADY et al. (1997). Both
NBFs contain Walker A and Walker B motifs (A,B)
An important recent advance in understanding ABC transporters came when the three-
dimensional crystal structure of the periplasmic histidine permease was solved (HUNG et al.,
Introduction 7
1998). This protein which is one of the most widely studied ABC transporters in
microorganisms imports histidine. The complex is composed of a soluble receptor, the
periplasmic histidine-binding protein, HisJ, and a four-subunit membrane-bound complex
(HisQMP2) composed of HisQ and HisM (the two hydrophobic subunits) and of two identical
HisP subunits (P2) that carry the highly conserved nucleotide-binding domain (DOIGE et al.,
1993) (Fig. 2 and Fig. 4). The membrane-bound complex of the histidine permease has been
purified and reconstituted into proteoliposomes (PLS), and shown to hydrolyse ATP and
translocate histidine in a manner strictly dependent on the presence of HisJ (LIU et al , 1997;
see Fig.2). In the absence of the binding protein, the complex hydrolyses ATP at a low rate
only (LIU et al., 1997).
The recent resolution of the three-dimensional structure of HisP at 1.5 Å clearly shows
the presence of an ATP-binding pocket containing an ATP molecule (HUNG et al., 1998). The
structure provides a model for the binding of ATP to an NBF and thus a basis for
understanding properties of ABC transporters such as SUR1.
Fig. 4 Transmembrane topology of HisQMP2. For details see text.
HisQMP2
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1.2.2. Cloning of sulfonylurea receptors
In 1995 AGUILAR-BRYAN et al. succeeded in purifying the high-affinity sulfonylurea receptor
(SUR1) from HIT T15 cells (a hamster B-cell line). After microsequencing of the amino-
terminus, the receptor was cloned from cDNA libraries of HIT T15 cells and RINm5F cells (a
rat insulinoma cell line). In 1996, two iso-forms of the sulfonylurea receptor were cloned:
SUR2A from rat brain and SUR2B from mouse heart (CHUTKOW et al., 1996; INAGAKI et al.,
1996; ISOMOTO et al., 1996). SUR2A and SUR2B are splice products of a single gene,
differing only in their C-termminal 42-45 amino acids (ISOMOTO et al., 1996). While the RNA
for SUR2A was observed mainly in heart and skeletal muscle, the RNA for SUR2B could be
detected in all examined tissues (INAGAKI et al., 1996 ISOMOTO et al., 1996).
Due to the distinct pharmacology and tissue distribution of the two iso-forms, it is
assumed that SUR2A represents the sulfonylurea receptor of heart and skeletal muscle and
SUR2B that of the vascular smooth muscle (ISOMOTO et al., 1996).
1.2.3. Mutations in SUR1 and KIR6.2 cause PHHI
Defects in four genes (Glucokinase, glutamate dehydrogenase, SUR1 and KIR 6.2) are known
to cause familial persistent hypoglycemia of infancy, PHHI (THOMAS et al., 1995, 1996a and
b; AGUILAR-BRYAN and BRYAN,1996; DUNNE et al., 1997). Mutations in SUR1, however, are
the most common cause (NESTOROWICZ et al., 1998) and up to now more than 40 are known.
All seem to be recessive. However, detailed studies on heterozygotes have not yet been done,
so it cannot be excluded that the heterozygous state is associated with a slight disturbance in
insulin secretion.
1.2.3.1. PHHI results as a consequence of reduced open probability of SUR1/KIR 6.2 channels
On the basis of their functional effects, mutations in SUR1 may be grouped into two classes.
Class I mutations result in the total loss of functional KATP-channel activity (e.g. F1388),
while class II mutations impair the ability of MgADP to enhance KATP-channel activity (e.g.
G1479R). The latter mutations abolish the ability of the channel to respond to changes in
metabolism and cause it to be permanently closed in the intact B-cell.
Both classes of PHHI mutations result in a lack of KATP-channel activity in the B-cell,
even at low blood glucose concentrations. This results in a continuous depolarisation of the B-
cell and a high resting intracellular Ca2+ concentration, which explains the constitutive insulin
secretion characteristic of PHHI patients (for a review see ASHCROFT and GRIBBLE, 1999).
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1.2.3.2. Incidence and clinical presentation of PHHI
The disease which is characterised clinically by excessively elevated circulating insulin
concentrations despite severe hypoglycemia (STANLEY and BAKER, 1976; AYNSLEY-GREEN,
1981; LANDAU et al., 1982) is most frequently diagnosed in the newborn or in infants,
although a number of cases have been reported in adults as well (HARNESS et al., 1981). In a
non-inbred Caucasian population it is estimated to occur at a frequency of 1 in 50,000 live
births (BRUINING, 1990). However, reported incidence is 1 per 2.675 live births in an arabic
population with a high degree of consanguinity (MATTHEW, et al., 1988). An approximate
calculation using the Hardy-Weinberg formula suggests that the frequency of the
heterozygous genotype in the general population is ~0.9%, or ~450 times that of the recessive
homozygote.
The clinical presentation of PHHI is variable (LANDAU and SCHILLER, 1991). Some
patients develop severe hypoglycemia minutes to hours after birth while others do not have
severe symptoms for several weeks or months. The clinical symptoms of both the severe and
the milder forms of the disease have been noted to diminish with age (STANLEY and BAKER,
1976; GRANT et al., 1986; LANDAU and SCHILLER, 1991).
1.3. Modulation of KATP channel activity
1.3.1. Cytosolic nucleotides
KATP-channels are inhibited by intracellular ATP in the presence or absence of Mg (IC50 =
10µM; COOK and HALES, 1984). This effect of ATP does not require hydrolysis of the
nucleotide as it can not be imitated by non hydrolysable ATP-analogues like AMP-PNP or
AMP-PCP. In addition to ATP, free ADP, diadenosinopolyphosphate, free GTP and GDP
reduce KATP-channel activity (COOK and HALES, 1984; MARTIN et al., 1998, RIBALET and
CIANI, 1987). The binding site for these inhibitory nucleotides is localised on KIR6.2, most
probably within the intracellular proximal C-terminal region (see Fig. 1) (TUCKER et al., 1997,
1998; DRAIN et al., 1998; MARKWORTH et al., 2000). The Mg-complexes of cytosolic
nucleotides like ADP and GDP stimulate KATP channel activity in the presence as well as in
the absence of inhibitory ATP (DUNNE and PETERSEN, 1986a and b; FINDLAY, 1987).
A rise in the ratio of cytosolic concentrations of ATP and ADP thus leads to an
inhibition of KATP channel activity and consequently to depolarisation of the plasma
membrane, opening of voltage-dependent Ca2+ channels and an increase in Ca2+ influx . The
resultant rise in cytosolic Ca2+ concentration induces the release of insulin (Fig.5).
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Fig. 5 Stimulation of insulin secretion in the B-cell (SCHWANSTECHER, 1994). Inhibition of
the opening activity of KATP channels by sulfonylureas or a rise in the ratio of cytosolic
concentrations of ATP and ADP ([ATP]/[ADP]), leads to depolarisation of the plasma
membrane, opening of voltage-dependent Ca2+ channels and an increase in Ca2+ influx . The
resultant rise in cytosolic Ca2+ concentration induces the release of insulin. An increase in the
[ATP]/[ADP] ratio occurs, if the mitochondrial citrate cycle is sufficiently activated by
nutrients (e.g. glucose). A rise in the extracellular glucose concentration increases the
phosphorylation of glucose through glucokinase (GK), the rate-limiting enzyme for the
metabolism of glucose in the B-cell.
1.3.2. Sulfonylureas
1.3.2.1. Structure
All sulfonylurea drugs used for lowering the blood glucose concentration have common
structural features, a benzene-sulphonic acid and a urea group (Fig. 6; PANTEN et al., 1992)
Tolbutamide is regarded as a typical representative of the so-called first generation
sulfonylurea drugs. Up to the introduction of glibenclamide (B in Fig. 6), it was the most
frequently used drug in the therapy of type II diabetes mellitus. Glibenclamide was the first
commercially available second generation sulfonylurea (AUMÜLLER et al., 1966) and is the
most prescribed oral antidiabetic drug in the world. While the first generation sulfonylurea
drugs (e.g. tolbutamide) have to be administered in gram/day doses, the second generation
drugs (e.g. glibenclamide and glipizide) are given in milligram/day doses. An additional
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carboxamido group and its substituents lead to an increased effectiveness of these molecules
(Fig. 6).
Sulfonylurea compounds are weak organic acids which are mostly anionic at
physiological pH. However, their non-dissociated forms are very lipophilic (PANTEN et al.,
1989).
A
B
C
Fig. 6 Structural formula of tolbutamide (A), glibenclamide (B), glipizide (C).
1.3.2.2. Mechanism of action
Sulfonylureas stimulate the secretion of insulin from pancreatic B-cells. This effect is
independent of the presence of nutrients (e.g. glucose) or other stimuli of insulin secretion
(MALAISSE et al., 1967; GORUS et al., 1988). It is based on the fact that these substances
reduce the K+ permeability and thus depolarise the B-cell membrane (Fig. 5; DEAN and
MATTHEWS, 1968; MATTHEWS, 1985; HENQUIN, 1987). The depolarisation of the plasma
membrane leads to an opening of voltage-dependent Ca2+ channels and an increase in Ca2+
influx into the cytosol. The resultant rise in the cytosolic Ca2+ concentration induces the
release of insulin (HENQUIN , 1987).
Patch-clamp experiments show that the sulfonylurea-induced decrease of K+
permeability is due to an inhibition of the opening activity of the KATP channel in the B-cell
membrane (Fig. 5).
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1.3.3. Potassium channel openers
1.3.3.1. Introduction
KCOs comprise a structurally diverse group of substances which activate KATP channels.
These drugs [e.g. benzopyranes such as cromakalim (D in Fig. 7) or levcromakalim,
nicotinamides such as nicorandil (E in Fig. 7), pyrimidine derivatives such as minoxidilsulfate
(F in Fig. 7), cyanoguanidines such as pinacidil (B in Fig. 7) or P1075 (C in Fig. 7) and
benzothiadiazines such as diazoxide (A in Fig. 7)] increase the outflow of 86Rb+ or 42K+ in
efflux experiments with vascular smooth muscle (COOK and QUAST, 1990), resulting in
hyperpolarisation, a reduced activity of voltage-dependent Ca2+ channels and a reduction of
electrical activity. The resultant decrease in the cytosolic Ca2+ concentration induces, for
example, an inhibition in the activity of secretory cells or a relaxation of muscle cells
(EDWARDS and WESTON, 1995)
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Fig. 7 Chemical structures of diazoxide (A), pinacidil (B), P1075 (C), cromakalim (D),
nicorandil (E) and minoxidilsulfate (F). In case of diazoxide and pinacidil, the forms
prevailing in the tautomeric balance are shown (WOHL, 1970; PETERSEN et al., 1978). The
dissociating protons are indicated by « (pKa = 8.6 for diazoxide; pKa = 10.8 for pinacidil)
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1.3.3.1.1. Diazoxide
Diazoxide (A in Fig. 7) a substance related to sulfonylureas, inhibits insulin secretion in
pancreatic B-cells of (SELZER and ALLEN, 1965; PORTE, 1968). Moreover, it induces
hyperglycemia (DOLLERY et al., 1962; TALBACHNIK and GULBENKIAN, 1968) and causes
relaxation of smooth vascular muscles in concentrations similar to those required for the
effect on pancreatic B-cells (GILMAN et al., 1985; QUAST and COOK, 1989).
The observation that diazoxide induces a rise of 86Rb-efflux in B-cells provided first
clues to the mechanism of action of this substance (HENQUIN and MEISSNER, 1982). Increased
86Rb-efflux coincided with hyperpolarisation of the cells and suppression of normal electrical
activity. HENQUIN and MEISSNER (1982) concluded that inhibition of insulin secretion from
B-cells by diazoxide is due to an increase in K+ permeability of the cell membrane. A few
years later patch-clamp studies revealed that diazoxide acts through the same KATP channel
that is closed by sulfonylureas (Fig. 6; TRUBE et al., 1986). In cell-attached experiments,
diazoxide antagonised both nutrient- and tolbutamide-induced channel inhibition.
In cultured neurones and brain slices, it was shown that diazoxide increases the
opening probability of the neuronal KATP channel as well (OHNO-SHOSAKU and YAMAMOTO,
1992; SCHWANSTECHER and PANTEN, 1994). Activation of the KATP channel of smooth
vascular and cardiac muscle cells was also observed (BEECH et al., 1993; KAJIOKA et al.,
1991; NELSON and QUAYLE, 1995; D’HAHAN et al., 1999).
1.3.3.1.2. Pinacidil
Pinacidil (B in Fig. 7) also belongs to the group of KCOs (BRAY et al., 1987; COOK et al.,
1988). This substance is a racemate, with the (-)-enantimer possessing a considerably stronger
potassium channel-opening effect (COOK et al., 1988). In addition to pinacidil, more potent
KCOs have been synthesized, such as P1060 (IBBOTSON et al., 1993) and P1075 (C in Fig. 7;
BRAY and QUAST, 1992).
In smooth muscle cells, very low concentrations of pinacidil have been shown to
activate K+-outflow (COOK and QUAST, 1990; QUAST, 1992). The substance can open KATP
channels in B-cells, neurons and in heart as well (GARRINO and HENQUIN, 1987;
SCHWANSTECHER et al., 1992c; SCHWANSTECHER 1994; SCHWANSTECHER and BASSEN, 1997;
ESCANDE et al., 1988 and 1989). Specific binding of [³H]P1075 (C in Fig. 7) has been
detected in intact aortic-rings of the rat (BRAY and QUAST, 1992).
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1.3.3.1.3. Other potassium channel openers
Of all KCOs only diazoxide and pinacidil induce an increase in the opening probability of
KATP channels in B-cells. Nicorandil (E in Fig. 7) is ineffective whilst minoxidil sulphate (F in
Fig. 7) and cromakalim (D in Fig. 7) induce channel inhibition (PLANT et al., 1989). For all
these substances, the  effects on insulin secretion correspond well to their effects on the KATP
channel.
The KATP channel in cardiac muscle cells is not only activated by pinacidil and
diazoxide but also by cromakalim, RP49356 and nicorandil (ESCANDE et al., 1988 and 1989;
THURINGER and ESCANDE, 1989; SHEN et al., 1991). In addition to pinacidil and diazoxide, a
series of other KCOs are effective on the smooth muscle, e.g. levcromakalim, nicorandil and
minoxidilsulphate (WESTON and EDWARDS, 1992).
1.3.3.2. Therapeutic potential
The known KCOs (with the exception of diazoxide) show a relative specificity for vascular
and non-vascular smooth muscle (QUAST, 1996).
These substances effectively lower blood pressure and could therefore be useful in the
treatment of hypertension and other cardiovascular diseases (e.g. angina pectoris) (EDWARDS
and WESTON, 1990; QUAST, 1992; LAWSON, 1996a and b). In concentrations lowering blood
pressure KCOs have little effect on the central nervous system. This is most probably due to
poor penetration of the substances through the blood-brain barrier. In addition, the substances
have no effect on plasma insulin levels at therapeutic concentrations (QUAST and COOK,
1989). Diazoxide is an exception in this case, as it lowers blood pressure and inhibits insulin
secretion (GILMAN et al., 1985).
Levcromakalim (unlike verapamil or nitroprusside sodium) selectively improves
collateral blood perfusion in isolated rabbit ear after arterial occlusion (RANDALL and
GRIFFITH, 1992). In vivo, a series of KCOs (levcromakalim, aprikalim, nicorandil and
pinacidil) protects the myocardium against the residual effects of transient ischaemia (GROSS,
1991; GROVER, 1991; ESCANDE and CAVERO, 1992; GROSS and AUCHAMPACH, 1992a;
AUCHAMPACH et al., 1994). Cardioprotection is abolished by glibenclamide (GROSS and
AUCHAMPACH, 1992b).
KCOs could also be suitable for treating further illnesses. In several animal models of
epilepsy, it was shown that these substances reduce or prevent the activity of seizures
(GANDOLFO et al 1989). In clinical studies, cromakalim (0.5 mg per day) lead to an
improvement of symptoms in asthma patients (WILLIAMS et al., 1990). However, clinical
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application of KCOs is hampered by its insufficient tissue selectivity. Therefore, development
of highly efficient drugs against diseases like asthma, hypertension, ischaemia, arrhythmia
and epilepsy will most probably require development of tissue-selective compounds.
1.3.3.3. Identification of the receptor binding sites for KCOs
In membranes from B-cells, insulin-secreting tumour cells and cerebral cortex, diazoxide and
pinacidil have been shown to inhibit high-affinity binding of [³H]glibenclamide
(SCHWANSTECHER and RIETZE, 1990; SCHWANSTECHER et al., 1990, 1991a and b, 1992a, b, c
and d). These effects required the presence of MgATP and were not observed in the absence
of Mg2+ or presence of non-hydrolysable ATP- analogues. The findings indicated that binding
of KCOs to their receptor site requires hydrolysis of ATP and that the binding sites for KCOs
and sulfonylureas are coupled in a negative allosteric manner. SCHWANSTECHER et al. (1998)
have shown that the receptor binding site for KCOs is localised on SURs and that a
conformational change induced by ATP binding and hydrolysis in both NBFs presumably
results in a strong increase in KCO affinity and thus is necessary for binding of KCOs (see
also UHDE et al., 1999). Non-hydrolysable ATP analogues, such as AMP-PNP and AMP-PCP
as well as ADP in the presence of an ATP capturing system were not able to induce KCO
binding. For the conformational change divalent cations are required and have a rank-order
effectiveness (Mg = Mn > Zn > Ca > Sr) characteristic for ATPase-activity of other ABC-
proteins (SCHWANSTECHER et al., 1998).
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2. Aims of the study
The aims of the study were:
(1) To analyze the effect of PHHI-inducing point mutations on diazoxide and glibenclamide
binding to SUR1.
(2) To establish and test a structural model for the NBFs of SUR1 based on homology
modeling.
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3. Materials and methods
3.1. Cultivation, passaging and preservation of COS7-cells
3.1.1. Solutions and media for cell culture
A) Penicillin/streptomycin stock solution (20000 IU/ml and/or 20000 µg /ml)
1.2 g of penicillin G-sodium (Nr. 321-42, Biochrom) and 2.0 g streptomycin sulfate (Nr. 331-26,
Biochrom) were dissolved in 100 ml 0.9% sodium chloride solution and stored at -20°C.
B) Dulbecco´s Modified Eagle´s medium (DMEM) + 10% FCS
13.5 g DMEM (powder; Nr. T 043-10, Biochrom) and 2.2 g of sodium hydrogencarbonate (Nr.
6329, Merck; final concentration 26 mM) were dissolved in approx. 800 ml bidistilled water. 5
ml of the penicillin/streptomycin stock solution (final concentration 100 IU/ml and/or 100 µg/ml)
were added and the solution was adjusted to pH 7.15 with 1N HCl or 1N NaOH, respectively.
The volume was filled up to 1000 ml with bidist. water. The solution was sterile-filtered using a
stainless steel vacuum filtration apparatus (Nr. SM 16268 107500, Sartorius) with preliminary
filter (Nr. 13400-130 K, Sartorius) and main filter (0.2 µm; Nr. 11307-142, Sartorius). The
medium was stored at 4°C for up to 8 weeks. Immediately before use, 100 ml of foetal calf serum
(FCS; sterile-filtered, Kraeber Ltd. & Co; and heat-inactivated for 30 mins at 56°C) were added
and the resultant medium was kept in a water bath at 37°C.
C) Freezing medium (DMEM + 20% FCS)
Under laminar air flow 3 ml of FCS were added to 12 ml DMEM (+ NaHCO3 and
penicillin/streptomycin; 3.1.1. B)
D) DMSO solution (Freezing medium + 20% DMSO)
Under laminar air flow 12 ml freezing medium (see 3.1.1. C) were mixed with 3 ml of sterile
DMSO (Nr. 1.02952, Merck).
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E) Trypsin/EDTA solution
100 ml of trypsin/EDTA solution (0.5 %/0.2% in 10x PBS without Ca2+ and Mg2+; L-2153, Bio-
chrom) were mixed with 900 ml sterile bidist. water, split up into 50 ml aliquots and stored at -
20°C.
F) Phosphate buffer (CMF- PBS)
8.0 g sodium chloride (Nr. 1.06404, Merck), 0.2 g potassium chloride (Nr. 1.04936, Merck), 1.15
g anhydrous disodium hydrogen phosphate (Nr. 1.06586, Merck) and 0.2 g potassium dihydrogen
phosphate (Nr. 4873, Merck) were dissolved in 900 ml bidist. water. The solution was adjusted to
pH 7.3 with 1N NaOH or 1N HCl, respectively and diluted to 1000 ml with bidist. water. The
solution was then autoclaved in aliquots.
3.1.2. Cultivation of COS7-cells
The COS7 cell (CV-1, Origin of SV40, GLUZMAN , 1981) is a derivative of a permanent kidney
cell line of the African green guenon (CV-1) infected with SV40 viruses (Simian Virus). The
monolayer cells were cultured at 37°C and 5% CO2 in DMEM with 10% FCS (see 3.1.1. B) and
passaged at intervals of 3 - 4 days.
3.1.3. Passaging of COS7-cells
After removing the culture medium from the Petri dishes the cells were carefully rinsed with 5 ml
CMF-PBS (see 3.1.1. F). 4 ml of trypsin/EDTA solution (see 3.1.1. E) were added to each of the
Petri dishes which were subsequently incubated for two to five minutes at 37°C. Trypsinization
was stopped by adding 3 ml of fresh culture medium (DMEM+10% FCS, 3.1.1. B). By gently
tapping the Petri dishes the cells still stucking to the ground were released. The cell suspension of
each Petri dish was then transferred to a sterile centrifuge tube (Sarstedt) and sedimented by
centrifugation (5 min at 100 g and 4°C, Heraeus Megafuge 1.0 R, rotor 2705, 900 rpm.). After
removing the supernatant and determining the cell count, each of the cell pellets was resuspended
in 10 ml culture medium and split up in a ratio of 1:3 to 1:5 into fresh Petri dishes so that approx.
500000 cells were placed in each dish.
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3.1.4. Cryopreservation of COS7-cells
For cryopreservation, the cells from densely grown culture plates were trypsinized as described in
3.1.3. They were subsequently resuspended in 1.5 ml of pre-cooled freezing medium (4°C, see
3.1.1. C) and mixed with 1.5 ml of cold DMSO solution (4°C, see 3.1.1. D). 1.5 ml aliquots of
this suspension were pipetted into a sterile pre-cooled cryotube (4°C). The tubes were kept at
-20°C for 1 h followed by -70°C for 24 h and then stored in liquid nitrogen (-196°C).
3.2. Preparation of mutations
3.2.1. Solutions for mutagenesis
A) PCR-primer (10 pmol/µl)
10 nmol lyophilized PCR-primer (Roth) were dissolved in 100 µl autoclaved bidist. water. 80 µl
of this solution were autoclaved and diluted with 720 µl bidist. water.
B) 0.5 M EDTA (pH 8.0)
93.1g ethylenediaminetetraacetic acid (EDTA; Nr.1.08418, Merck) were dissolved in 350 ml
bidist. water, adjusted with NaOH to pH 8.0 (Nr. 106498, Merck). The solution was made up to
500 ml with water and autoclaved.
C) TAE buffer
242 g Tris (4855.2, Roth), 57.1 ml glacial acetic acid (Nr. 5421.3, Bernd Kraft GmbH) and 100
ml 0.5 M EDTA solution were dissolved in bidist. water to a final volume of 1000 ml. 20 ml of
this stock solution were diluted with bidist water to 1000ml.
D) Loading buffer
250 mg xylene cyanol (Nr. 1.10590, Merck), 250 mg bromophenol blue (Nr. B-8026, Sigma), 25
g ficoll 400 (Nr. 17-0400-01, Pharmacia) and 10 ml 0.5 M EDTA were dissolved in bidist. water
to make 100 ml. The buffer was then autoclaved.
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3.2.2. QuikChange site-directed mutagenesis
Mutations were induced by the “QuikChange site-directed mutagenesis” method (see 4.1. for
further details). The PCR was carried out in a Biometra Personal Cycler in 0.5 ml Eppendorf
safe-lock reaction tubes (Nr. 0030 121.23). Two different oligonucleotide primers (25-45 bases)
were used. Each reaction tube contained 1 µl of dNTP mix, 5-50 ng of double stranded DNA
(dsDNA) as template, 125 ng of oligonucleotide primer 1, 125 ng of oligonucleotide primer 2, as
well as 5 µl DNA polymerase reaction buffer, 10 times concentrated, and 2.5 units Pfu DNA-
polymerase (both Nr. 600153, Stratagene) in a total volume of 50 µl. The sets were overlayed
with about 100 µl mineral oil (Nr. M 5904, Sigma). Each PCR reaction comprised 12 to 18
reaction cycles. In each cycle, the PCR reaction was heated for 1 min at 95°C to denature the
DNA, followed by 1 min at a temperature of about 5°C below the melting temperature of the
primer (between 50 and 65°C), which allowed binding to the template DNA. dsDNA could be
extended by action of the polymerase. Finally, as the reaction mixture was heated for 2
minutes/Kb of plasmid length to 68°C (which is the optimal working temperature of the
polymerase) a complete dsDNA including the vector was obtained (see 4.1.2).
3.2.3. Digestion of the products
1 µl of Dpn I restriction enzyme (10 U/µl) was added directly to each amplification reaction and
the reaction mixture was then spinned down in a microcentrifuge for 1 min at 13000 rpm. Finally,
each reaction was incubated at 37°C for 1 hour to digest the parental (i.e. the non-mutated)
supercoiled dsDNA.
3.3. Transformation and plasmid preparation
3.3.1. Solutions
A) Glucose solution (1 M, sterile)
19,82 g of glucose monohydrate (Nr. 8342, Merck) were dissolved in 90 ml bidist. water. The
solution was then made up to 100 ml with bidist. water and subsequently sterile-filtered.
Filtration was carried out using “Filtropur S 0.2” pore size 0.2 µm, Nr. 83.1826.001, Sarstedt).
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B) Potassium chloride stock solution (0.25 M)
1.86 g of potassium chloride (Nr. 4936, Merck) were dissolved in 100 ml bidist. water. The
solution was adjusted to pH 7.0 with 1 N KOH and autoclaved.
C) Luria-Bertani medium (LB medium)
10 g Select Peptone 140 (Nr. 30392-021, Gibco), 5 g yeast extract (Nr. 30393-029, Gibco) and 10
g sodium chloride (Nr. 1.06404, Merck) were dissolved in 950 ml bidist. water. The solution was
adjusted to pH 7.0 with 5 N NaOH, made up to 1000 ml and subsequently autoclaved.
D) SOB medium
20 g Select Peptone 140 (Nr. 30392-021, Gibco), 5 g yeast extract (Nr. 30393-029, Gibco) and
0.5 g sodium chloride (Nr. 1.06404, Merck) were dissolved in 950 ml bidist. water. Then 10 ml
of 0.25 M potassium chloride solution were added (see 3.3.1 B). The solution was adjusted to pH
7.0 with 5 N NaOH filled up to 1000 ml and subsquently autoclaved.
E) SOC-medium
SOB medium (see 3.3.1. D) was cooled to approx. 60°C after being autoclaved. 2 ml of a 1 M
sterile glucose solution were added (see 3.3.1. A) to 100 ml SOB medium.
F) Ampicillin stock solution (50 mg/ml)
1 g ampicillin (Nr. 835242, Boehringer Mannheim) was dissolved in 20 ml bidist. water, sterile-
filtered and stored at -20°C in the dark. Sterile filtration was carried out as described (3.3.1. A).
G) LB-Agar plates with 100 µg/ml ampicillin
15 g Agar-Agar (Nr. 5210.1, Roth) were added to 1 l LB medium (see 3.3.1. C) and subsequently
the medium was autoclaved. When the medium was cooled down to approx. 50°C, 2 ml of
ampicillin stock solution (see 3.3.1 F) were added and the plates were casted under laminar air
flow (approx. 30 ml per Petri dish of 94 mm diameter). The plates were stored at 4°C up to use.
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H) Medium A for production of transformation competent cells
0.493 g of magnesium sulphate (Nr. 5886, Merck) and 0.4 g of glucose monohydrate (Nr. 8342,
Merck) were dissolved in 200 ml LB medium (see 3.3.1 C) and the solution was subsequently
sterilized as described (3.3.1. A).
I) Medium B for production of transformation competent cells
36 ml glycerin (anhydrous, pure, Nr. 4093, Merck), 12 g of polyethylene glycol 8.000 (Nr. P-
2139, Sigma) and 0.296 g of magnesium sulphate (Nr. 5886, Merck) were dissolved in 100 ml
LB medium (see 3.3.1 C) and the solution was subsequently sterilized as described (3.3.1.A).
J) Resuspending buffer for plasmid preparation
6.066 g Tris (Nr. 100 849, Paesel + Lorei) and 3.722 g EDTA (Nr. 1.08418, Merck) were
dissolved in 800 ml sterile bidist. water, The pH-value was adjusted to 8.0 with 1 N HCl and the
solution was filled up to 1000 ml with sterile bidist. water. In 100 ml of this solution 10 mg
RNAse A (Cat. No. 19101, Qiagen) were dissolved. The resuspending buffer could be stored at
4°C for up to 6 months.
K) Lysis buffer for plasmid preparation
8 g of NaOH (Nr. 6462, Merck) and 10 g sodium dodecylsulfate (special quality, Nr 1028693,
Boehringer Mannheim) were dissolved in 1000 ml sterile bidist. water.
L) Neutralization buffer for plasmid preparation
294.42 g of potassium acetate (for molecular biology, no. 1.04830, Merck) were dissolved in 500
ml sterile bidest. water, the pH-value was adjusted with glacial acetic acid to 5.5 and completed
with sterile bidest. water to 1000 ml.
M) Equilibrium buffer for plasmid preparation
43.83 g of sodium chloride  (no. 1.06404, Merck) and 10.46 g 4-morpholinepropanesulfonic acid
(MOPS; Nr. 6979.2, Roth) were dissolved in 700 ml sterile bidist. water and the pH-value was
adjusted to 7.0 with 1 N NaOH. After addition of 156.25 ml of ethanol and 1.5 ml triton X-100
(Nr. 789704, Boehringer Mannheim) the buffer was filled up with sterile bidist. water to 1000 ml.
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N) Washing buffer for plasmid preparation
58.44 g of sodium chloride (Nr. 1.06404, Merck) and 20.92 g 4-morpholinepropanesulfonic acid
(MOPS; Nr. 6979.2, Roth) were dissolved in 1500 ml sterile bidist. water and the pH-value was
adjusted with 1 N NaOH to 7.0. After addition of 312.5 ml of ethanol the solution was filled up
with sterile bidist. water to 2000 ml.
O) Elution buffer for plasmid preparation
73.05 g of sodium chloride (Nr. 1.06404, Merck) and 6.066 g Tris (Nr. 100 849, Paesel + Lorei)
were dissolved in 800 ml sterile bidist. water and the pH-value was adjusted with 1 N HCl to 8.5.
After addition of 156.25 ml of ethanol the solution was filled up with sterile bidist. water to 1000
ml.
P) Tris/EDTA buffer
1.21 g Tris (Nr. 100 849, Paesel + Lorei) and 372.2 mg EDTA (no. 1.08418, Merck) were
dissolved in 800 ml bidist. water, the pH-value was adjusted with 1 N HCl to 8.0 and the solution
was filled up with bidist. water to 1000 ml. The buffer was split up into aliquots of 100 ml and
autoclaved.
3.3.2. Production of transformation competent cells
The production of transformation competent cells was done by use of polyethylene glycol (PEG
method). 5 ml LB medium (see 3.3.1 C) were inoculated with E. coli cells (Epicurian Coli XL1 -
Blue, Stratagene) and incubated overnight at 37°C in a shaking incubator (Innova 4300, New
Brunswick Scientific). The next morning, 50 ml medium A (see 3.3.1. H) were inoculated with
500 µl of the overnight culture and incubated at 37°C in the shaking incubator until an optical
density of 0.55 at 578 nm was achieved (spectrophotometer Uvikon 932, Kontron Instruments).
Subsequently, the bacterial suspension was transferred to a centrifuge tube and incubated 10 min
on ice, then 10 min at 4°C and centrifuged at 1500 g (cool centrifuge GR 2022 with rotor 290.9,
Jouan; 2900 rpm). The sediment was resuspended in 500 µl ice-cold medium A (see 3.3.1. H).
After addition of 2.5 ml medium B (see 3.3.1 I) the bacterial suspension was mixed carefully and
split up into aliquots of 100 µl. The competent cells were frozen at -80°C and stored for up to one
year.
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3.3.3 Transformation
50 µl competent cells (see 3.3.2.) were pipetted into a sterile reaction tube. After addition of 2 µl
of plasmid DNA solution (50 µg/ml) it was shaken carefully and kept for 30 minutes on ice. The
solution was incubated in a water bath for 90 seconds at 42°C and was immediately transferred
on ice for two minutes. After addition of 500 µl SOC-Medium (see 3.3.1. E) the cells were kept
for an hour at 37°C in the shaking incubator (Innova 4300, New Brunswick Scientific).
Subsequently, the solution was plated onto a LB-Agar plate (see 3.3.1. G). Following several
hours under laminar air flow at room temperature the solution was incubated overnight at 37°C
(CO2-incubator, BB6220, Heraeus Instruments). The next day, about twenty colonies were
picked. Each of the colonies was supplied with 5 ml LB medium (see 3.3.1 C) and incubated in
the shaking incubator overnight at 37°C. Several of the colonies were tested to verify the point
mutation. For this purpose they were incubated with an appropriate restriction enzyme (see e.g.
4.1.3) and separated by electrophoresis. A putatively correct colony gives bands at the expected
lengths (for an example see Fig. 11). This colony was then transferred to 10 ml LB medium (see
3.3.1. C), to which 20 µl ampicillin stock solution were added (see 3.3.1. F). This bacterial
suspension was finally incubated in the shaking incubator overnight at 37°C.
3.3.4. Plasmid preparation
On the following day the bacteria were separated by centrifugation (Jouan cool centrifuge GR
2022, Rotor AG 100.18, 6000 g, 4°C, 15 min). The pellet was resuspended in 4 ml resuspension
buffer (see 3.3.1. J). After addition of 4 ml lysis buffer (see 3.3.1. K) the suspension was
cautiously mixed and incubated 5 min at room temperature. 4 ml of neutralization buffer (see
3.3.1. L) were added, carefully mixed and the suspension was incubated 15 mins on ice. After
centrifugation of the bacterial lysate (Jouan cool centrifuge GR 2022, rotor AG 16.20, 30.000 g,
4°C, 30 mins), the supernatant was immediately removed and added to a column (Qiagen-tip 20,
Nr. 10023, Qiagene) which had been equilibrated with 4 ml equilibrium buffer (see 3.3.1. M).
Subsequently, the column was washed twice with 10 ml of washing buffer (see 3.3.1. N) and the
plasmid DNA was eluted with 5 ml elution buffer (see 3.3.1. O) into a sterile tube. After
precipitation of the DNA with 3.5 ml isopropanol at room temperature and centrifugation (Jouan
cooling centrifuge GR 2022, Rotor AG 16.20, 25.000 g, 4°C, 30 min), the DNA precipitate was
washed twice in 70% ethanol, centrifuged again and dissolved in sterile Tris/EDTA buffer (see
3.3.1. P).
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3.3.5. Sequencing
Point mutations were verified by sequencing which was done by SEQLAB (Göttingen).
3.4 Transfection
3.4.1. Solutions for transfection
A) Diethylaminoethyl dextran stock solution
500 mg of diethylaminoethyl dextran (DEAE dextran, D 9885, sigma) were dissolved in 10 ml
bidest. water and autoclaved.
B) TBS buffer (Tris buffered saline)
Solution A:
80 g of sodium chloride (Nr. 1.06404, Merck), 3.8 g of potassium chloride (Nr. 4936, Merck), 2.0
g anhydrous disodium hydrogen phosphate (Nr. 1.06586, Merck) and 30 g Tris (Nr. 100840,
Paesel + Lorei) were dissolved in 900 ml bidist. water, adjusted to pH 7.5 with 1 N NaOH and
filled up with bidist. water to 1000 ml.
Solution B:
1.5 g calcium chloride (Nr. 2382, Merck) and 1.0 g of magnesium chloride (Nr. 5833, Merck)
were dissolved in 100 ml bidist water.
Both solutions were stored at 4°C.
For production of TBS buffer, 100 ml of solution A were mixed with 890 ml bidist. water.
Subsequently, 10 ml of solution B were added dropwise under stirring. The solution was sterile
filtered (see 3.1.1. B) and stored at 4°C.
C) DNA/DEAE dextran mixture
36.4 µl TBS (3.4.1. B) were mixed with 83.6 µl DEAE dextran stock solution (see 3.4.1. A) and
20 µg plasmid-DNA were added to 60 µl TBS. Subsequently, both solutions were carefully
mixed.
D) HBSS buffer (Hepes buffered saline solution)
8 g sodium chloride (Nr. 1.06404, Merck), 0.37 g potassium chloride (Nr. 4936, Merck), 107.7
mg anhydrous disodium hydrogen phosphate (Nr. 1.06586, Merck) and 5 g HEPES (Nr. 242608,
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Boehringer Mannheim) were dissolved in 900 ml bidist. water, adjusted to pH 7.05 with 1 N
NaOH and filled up with bidist. water to 1000ml. The solution was sterile-filtered (see 3.1.1. B)
and stored at 4°C.
E) 10% FCS in TBS
3.6 ml TBS (see 3.4.1. B) were mixed with 0.4 ml of sterile-filtered FCS under laminar air flow.
The solution was freshly prepared each time.
F) 10% DMSO in HBSS
Per plate, 4.5 ml HBSS (see 3.4.1. D) were mixed with 0.5 ml autoclaved DMSO (Nr. 1.02952,
Merck) under laminar air flow. The solution was freshly prepared each time.
G) Tris buffer pH 7.4 (1 M)
36.3 g Tris (Nr. 100 840, Paesel + Lorei) were dissolved in 200 ml bidist. water, adjusted to pH
7.4 with 37% HCl, filled up with bidist. water to 300 ml and autoclaved.
H) Sodium chloride solution (5 M)
2.92 g of sodium chloride (Nr. 1.06404, Merck) were dissolved in 10 ml bidist. water and the
solution was then autoclaved.
I) Chloroquine stock solution
51.6 mg chloroquine (Nr. C-6628, Sigma) were dissolved in 9.22 ml bidist. water and mixed with
0.5 ml 1 M Tris buffer (see 3.4.1 G) pH 7.4 and 0.28 ml of 5 M sodium chloride solution (see
3.4.1. H). This solution was then sterile-filtered (see 3.1.1. B), split up in to aliquots and stored in
the dark at - 20°C.
J) DMEM/100 µM chloroquine/2% FCS medium
Per plate, 200 µl FCS, 100 µl chloroquine stock solution (see 3.4.1. I) and 9.7 ml DMEM (see
3.1.1. B) were mixed. The solution was freshly prepared under laminar air flow each time.
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3.4.2. Transfection by means of the DEAE dextran method
The transient transfection of COS7 cells (see 3.1.2.) was carried out by means of a modified
DEAE dextran method. 24 hours before transfection COS7 cells were plated at a density of
500000 cells per 94 mm Petri dish (see 3.1.1. B) and allowed to attach overnight. The next day,
DNA/DEAE dextran mixture (see 3.4.1. C) was prepared and incubated 30 min at room
temperature. During this incubation the FCS solution in TBS (see 3.4.1. E) was prepared and the
cells were washed twice with 8 ml HBSS (see 3.4.1. D). The DNA/DEAE dextran mixture was
diluted with 4 ml of the freshly prepared FCS solution in TBS, cautiously mixed and added to the
washed cells. The plates were incubated under 5% CO2 for four hours at 37°C (CO2 incubator
BB6220, Heraeus Instrument). During this time DMSO solution in HBSS (see 3.4.1. F) and
chloroquine medium (see 3.4.1 J) were prepared. The chloroquine medium was protected against
light and both solutions were kept at 37°C.
Subsequently the DNA/DEAE dextran solution was removed and 5 ml of the warmed
DMSO solution (see 3.4.1. F) were added. After 2 min of incubation at room temperature the
DMSO solution was sucked off and the chloroquine medium was added. After few hours of
incubation at 37°C under 5% CO2 the cells were washed twice with 8 ml HBSS and 12 ml culture
medium (see 3.1.1. B) were added.
3.5. Membrane preparation
3.5.1. Solutions
A) Phosphate buffer (NaCl 137 mM, KCl 2.7 mM, Na2HPO4 6.5 mM, MgCl2 0.5 mM, CaCl2 0.7
mM)
12 g sodium chloride (Nr. 1.06404, Merck), 300 mg potassium chloride (Nr. 4936, Merck), 1.725
g anhydrous disodium hydrogen phosphate (Nr. 1.06586, Merck), 150 mg magnesium chloride
(Nr. 5833, Merck) and 150 mg calcium chloride (Nr. 2382, Merck) were dissolved in 1000 ml
bidist. water. The pH-value was adjusted with 1 N HCl to 7.4 and the volume was filled up with
bidist. water to 1.5 l.
B) Phenylmethylsulfonylfluoride (PMSF 100 mM)
Immediately before use, 8.71 mg PMSF (Nr. P-7626, Sigma) were dissolved in 500 µl 99.9%
ethanol.
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C) Lysis medium (Tris 5 mM, PMSF 0.1 mM, pH 8.0)
60.5 mg Tris (Nr. 100 840, Paesel + Lorei) were dissolved in 90 ml bidist. water. 100 µl 100 mM
PMSF solution (see 3.5.1. B) were added and the pH-value was adjusted with 1 N HCl to 8.0.
The volume was filled up with bidist. water to 100 ml.
D) Homogenization medium (Tris 50 mM, PMSF 0.1 mM, pH 7.4)
303 mg Tris (Nr. 100 840, Paesel + Lorei) were dissolved in 40 ml bidist. water, 50 µl 100 mM
PMSF solution (see 3.5.1. B) were added and the pH-value was adjusted with 1 N HCl to 7.4.
The volume was filled up with bidist. water to 50 ml.
E) Tris buffer (5 mM)
60.5 mg Tris (Nr. 100 840, Paesel + Lorei) were dissolved in 90 ml bidist. water and the pH-
value was adjusted with 1 N HCl 7.4. The volume was filled up with bidist. water to 100 ml.
3.5.2. Preparation of membranes from COS7-cells
72 hours post-transfection the culture medium was removed from the culture plates and the cells
were washed with 5 ml phosphate buffer (3.5.1. A). After addition of 3 ml phosphate buffer cells
were harvested with a cell scraper. The cell suspension was transferred to tappered small tubes
and the culture plates were rinsed twice with 2 ml of rinsing buffer. The cells were then
sedimented 5 minutes at 100 g (4°C Heraeus Megafuge 1.0 R, rotor 2705, 900 rpm).
The sedimented cells of each tube were resuspended in 500 µl cold lysis medium (4°C,
3.5.1. C), transferred to a 1 ml glass homogenizer (Nr. 19, Kontes Glass Co, Vinelind, NJ, USA)
and kept on ice for 30 minutes. Subsequently, the suspension was homogenized mechanically
under ice cooling with 40 strokes a Teflon-glass homogenizer (500 rpm). For sedimentation of
cell fragments, this homogenate was centrifuged for 30 minutes at 4°C and 38000 g (cool
centrifuge GR 2022, rotor 2.20, Jouan). The pellets were resuspended in 100 µl cold
homogenization buffer each (3.5.1. D), rehomogenized by a glass homogenizer and resedimented
(1 h, 38000 g, as above). This second sediment ("membranes") was resuspended in 60 µl cold 5
mM Tris buffer (3.5.2. E). After rehomogenization with the glass homogenizer aliquots of the
suspension were filled into precooled cryo-tubes (Roth) and kept frozen at -196°C in liquid
nitrogen until binding studies were performed.
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3.6. Protein determination (modified according to Sigma, method Nr. TPRO-562)
3.6.1. Solutions
The following solutions were used for protein determination :
Reagent A: Bicinchoninic acid solution (Nr. B-9643, Sigma)
Reagent B: 4% (w/v) copper-2-sulfate pentahydrate (Nr. 2790, Merck)
Solution A: 5 ml reagent A and 0.1 ml reagent B well mixed
Protein standard: 1 mg/ml bovine serum albumin (Nr. 11924, Serva)
3.6.2. Procedure
For calibration the protein standard was diluted (see 3.6.1.) so that the solutions contained 0, 200,
400, 600, 800 and 1000 µg BSA/ml.
Determination of protein contents was done in a micro titrating plate (Nr. 82.1581, Sarstedt). For
each incubation set, 10 µl diluted protein standard solution or sample solution were added to 200
µl solution A (see 3.6.1.) and incubated for 30 mins at 37°C under shaking (Incubator SLT,
model IS 2.10). The samples were then left at room temperature for 5 min and the absorption at l
= 550 nm was determined in a micro titrating plate reader (SLT, model 340 ATTC). Evaluation
of the results was done with the "Easy-Fit"-program (version 5.47, SLT).
3.7. Binding experiments with COS membranes
3.7.1 Solutions
Standard buffer (Tris HCl 50 mM)
60.66 g Tris (100 849, Paesel + Lorei) were dissolved in 9000 ml bidist. water. The pH was
adjusted with HCl 37% to 7.40. The volume was filled up with bidist. water to 10 l. The buffer
was stored at 4°C for up to one week.
3.7.1.1. Stock solution of radio ligand
[³H]Glibenclamide-stock solution (3 nM; 51.4 Ci/mmol)
4 µl [³H]glibenclamide (250 µCi/250 µl, Order Nr. NET 1024, Dupont) were mixed with 40 ml
of standard buffer (see 3.7.1.). The concentration of [³H]glibenclamide was controlled by liquid
Materials and methods 30
scintillation counting and corrected if deviation from the set point (33840 dpm/100 µl) was more
than 5%.
3.7.1.2. Stock solutions of test substances
For every displacing ligand a stock solution was prepared, split up in aliquotes and stored at
-20°C. From these stock solutions, the required diluted solutions were prepared by successive
dilutions with standard buffer (see 3.7.1.). In case of diazoxide the dilutions were prepared with
bidist. water.
A) Diazoxide stock solution (10 mM)
3.356 mg diazoxide (Essex Pharma, MG 230.7) were dissolved in 1.5 ml 40 mM NaOH.
B) Glibenclamide stock solution (1 mM)
4.94 mg glibenclamide (Hoechst, MG 493) were dissolved under stirring in 10 ml 50 mM NaOH
overnight at 37°C.
C) MgATP solution (1mM)
2.25 mg ATP (Boehringer Mannheim, MG 605.2) were dissolved in 2700 µl 1 mM MgCl2.
3.7.2. Preparation of membranes
An aliquot of the membranes kept at -196°C (see 3.5.2.) was thawed at room temperature,
resuspended in standard buffer (see 3.7.1.), transferred into a 0.5 ml tube and sonicated on ice 8-
10 times for 1 second each (Sonifier B-12, Branson Sonic Power Company; output control: stage
7, duty cycle 25%, non pulsated; equipment: standard resonator). The membrane suspension was
diluted with standard buffer (see 3.7.1.) to the required volume.
3.7.3. Binding experiments
3.7.3.1. Principle of the filtration assay
Vacuum filtration is a common procedure for separation of free and bound ligands in radio ligand
binding studies (BENNETT, 1978; REPKE and LIEBMANN, 1987). During filtration, however, the
radioligand-receptor-complex is subjected radioligand-free washing buffer for a short period.
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Therefore, this procedure is recommended only for radioligand-receptor-complexes with
dissociation constants in the low nanomolar range (REPKE and LIEBMANN, 1987).
3.7.3.2 Incubation
Binding of [3H]glibenclamide to SUR1
The incubation medium contained [3H]glibenclamide in a concentration of 0.3 nM. Microsomal
protein was added in a final concentration of about 5 µg/ml. Non-specific binding was
determined by parallel incubation sets which contained 100 nM non-labeled glibenclamide.
Incubations were carried out in 2 ml-tubes without lids (Sarstedt) at room temperature. The final
concentrations of added glibenclamide or diazoxide are given in the results. They were adjusted
by addition of aliquots of the stock solutions (see 3.7.1.2.) to the incubation medium. Incubations
were started by addition of microsomal protein and terminated after 60 min by filtration.
3.7.3.3. Filtration and scintillation counting
The filtration equipment consisted of a 2 l-filter flask (connected to a vacuum pump,
Vacuubrand) with a set for membrane filters attached on top. Fiber glass filters (Whatman GF/B,
25 mm of diameter) which had been incubated in standard buffer at 4°C for 15 min were used
(see 3.7.1.). The incubation mixture of a sample (1 ml) was pipetted onto the filter and the filter
was subsequently washed three times with 4 ml of standard buffer cooled to 4°C each (see
3.7.1.). After rinsing, the filter was transferred to a scintillation vial (Mini Vial C, Roth). The
[3H]-content of the filter was determined after addition of 4 ml scintillation liquid (Rotiszint 22,
Roth) and equilibration (24 h, room temperature) in a liquid scintillation counter (Tri - Carb 2100
TR, Canberra-Packard).
3.8. Modeling
The model structure for the nucleotide binding folds of SUR1 was developed by H.-.J. HECHT
(National Institute für Biotechnological Research (GBF), Department of Structure Research
Braunschweig, Germany) using the crystal structure of the ATP-binding subunit of histidine
permease from Salmonella typhimurium as structural template. The program BRAGI
(SCHOMBURG and REICHELT, 1988) was used for sequence exchange and the program O (JONES,
1985) for visualisation. The pictures were drawn using MOLSCRIPT (KRAULIS, 1991) and
rendered using gl_render (ESSER L, unpublished) and POV-RaY™.
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3.9. Data evaluation
3.9.1. Statistics
Results are shown as mean ± SEM for N independent experiments with independent membrane
preparations. P values were calculated by the Mann-Whitney U-test with Bonferroni correction
for multiple comparisons (WALLENSTEIN et al., 1980), p < 0.05 was considered as significant
3.9.2. Specific binding
Specific binding was determined by subtraction of non-specific binding (s. 3.7.3.2.) from total
binding.
3.9.3. Equilibrium binding
The following equation was used for analysis of the relationship between substance concentration
and binding:
(1)    B = (100-k) / (1+(IC50 / [A])
n) + k            
B is the specific binding, [A] is concentration of free substance, IC50 is the half maximal
inhibitory concentration, n is the slope parameter (Hill coefficient) and k is an additive constant.
3.9.4. Dissociation constants
The dissociation constants (KD) for binding to SUR1 were calculated by use of the equation
(CHENG and PRUSOFF, 1973):
(2)    KD = IC50 / 1 + ([L] / KD(R))
from the IC50. KD is the dissociation constant of the displacing substance, [L] is the concentration
and KD(R) is the dissociation constant of the radioligand.
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3.9.5. Determination of diazoxide binding to SUR1
Diazoxide binding to SUR1 was determined by an indirect assay based on the displacement of
[3H]glibenclamide as follows:
(3)    Diazoxide (%) = (A-B)/(A-C) • 100,
A = [3H] (Dz)/[3H] (control), B = [3H] (Dz + [ATP])/[3H] ([ATP]) and C = [3H] (Dz +
[ATP]MAX)/[
3H] ([ATP]MAX). [
3H] is the amount of [3H]glibenclamide specifically bound in the
absence of further additions (control) or presence of 280 µM diazoxide (Dz) and/or [ATP];
[ATP]MAX = 100 µM.
3.9.6. Determination of ATP-induced inhibition of glibenclamide binding
100 µM MgATP inhibits high affinity binding of 0.3 nM [3H]glibenclamide to wild type SUR1
and it has been shown that this inhibitory effect is lost if ATP binding or hydrolysis in the NBFs
is eliminated by point mutations in the Walker motifs (SIEVERDING, 1998a). Thus, in this study,
the effect of point mutations was analysed on the inhibitory effect of ATP on [3H]glibenclamide
binding. Values are presented as percentage of the inhibitory effect of 100 µM MgATP in wild
type SUR1(24 ± 6 %).
3.9.7. Determination of Bmax
The number of sulfonylurea receptors (Bmax) was calculated from displacement of
[3H]glibenclamide through non-labeled glibenclamide by use of the equation (DEBLASI et al.,
1989):
(8)    Bmax = B0 • (K´D + [L]) / [L]
B0 is the number of receptors occupied in the presence of [L], K´D is the apparent dissociation
constant for glibenclamide and [L] is the concentration of [3H]glibenclamide (0.3 nM).
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4. Results
4.1 Application of the “QuikChange site-directed mutagenesis” method
For characterization of functional domains in SURs the “QuikChange site-directed
mutagenesis” method had to be established. With this method about 1-4 bases of the protein
can be exchanged, inserted or deleted. Thus it is possible to replace amino acids with others,
add new ones or delete any. Moreover, a basis triplet that encodes for an amino acid can be
transformed to a stop-codon, so that protein biosynthesis ends at this site and arbitrarily
shortened non-functional proteins develop. Through silent-mutations sites for restriction
endonucleases can be inserted in order to combine cDNAs of different SURs and develop
chimeras among different isoforms.
4.1.1. Principle of the method
The basic procedure (Fig. 8) utilizes a dsDNA vector with an insert of interest and two
synthetic oligonucleotide primers containing the desired mutation and a restriction site. The
oligonucleotide primers, each complementary to opposite strands of the vector, extend during
temperature cycling by means of Pfu DNA polymerase. On incorporation of the
oligonuclotide primers, a mutated plasmid containing staggered nicks is generated. Following
temperature cycling, the product is treated with the DpnI restriction enzyme. The Dpn I
endonuclease (target sequence: 5'–Gm6ATC-3') is specific for methylated and hemimethylated
DNA and is used to digest the parental DNA template and select for mutation-containing
synthesized DNA. DNA isolated from almost all Escherichia coli (E. coli) strains is dam
methylated and therefore susceptible to Dpn I digestion. The nicked vector DNA
incorporating the desired mutations is then transformed into E. coli (i.e., XL1-Blue
supercompetent cells). The transformation plates are incubated for > 16 hours at 37°C.
Between 50 and 800 colonies should be obtained.
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Fig. 8 Overview of the QuikChangeTM site directed mutagenesis method. For details see text.
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4.1.2. Design of mutagenic oligonucleotide primers:
Mutagenic primers introduce specific experimental mutations. They must be designed
individually according to the desired mutation. The following considerations should be made :
1. Both mutagenic primers must contain the desired mutation and anneal to the same
sequence on opposite strands of the plasmid. They should contain the restriction site of
certain restriction endonucleases.
2. Primers should be between 25 and 45 bases in length, and their melting temperature
(Tm) should be ~10°C above the extension temperature of 68°C. The following
formula is commonly used for estimating the Tm:
                                     Tm  = 81.5 + 0.41(%GC) –675 / N - % mismatch
N is the primer length in base pairs, %GC is the ratio of guanine and cytosine to
thymine and adenine in the primer and % mismatch is the number of changed bases
divided by the the number of bases in the primer.
3. The desired mutation (deletion or insertion) should be in the middle of the primer with
~10-15 bases of correct sequence on both sides.
4. The primers optimally should have a minimum GC content of 40% and should
terminate in one or more C or G bases.
In the present study point mutations were introduced into different parts of SUR1. The
generation of one of these point mutations is described here as an example, namely the
replacement of alanine in position 843 of SUR1 by aspartic acid (A843D). For this purpose
the cytosines (C) at positions 2552 and 2553 of hamster SUR1 cDNA were exchanged in
order to convert the triplet GCC encoding alanine to GAT encoding aspartic acid (Fig.9). This
change simultaneously generated a second Bgl II restriction site (AGATCT).
Subsequently, PCR was carried out as described (3.2.2) and the PCR product was
transformed using XL1-Blue supercompetent bacteria. To find a colony with the desired
mutation, the DNA of at least 20-30 single bacterial colonies was treated individually by the
restriction enzyme Bgl II. The treated DNA was then separated on an agarose gel by
electrophoresis and the resulting bands were stained with ethidium bromide. While cutting of
the wild type plasmid by Bgl II yielded two fragments of 6554 and 1250 bp in length, cutting
of the mutant produced three (5253, 1301 and 1250 bp; Fig.10).
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A Wild type sequence (2533 - 2568)
5'  CGTATCAGTGTGGCCAGAGCCCTCTACCAGCAGACC  3'
3'  GCATAGTCACACCGGTCTCGGGAGATGGTCGTCTGG  5'
B Mutation sequence (2533 - 2568)
5'  CGTATCAGTGTGGCCAGAGATCTCTACCAGCAGACC  3'
3'  GCATAGTCACACCGGTCTCTAGAGATGGTCGTCTGG 5'
C Mutagenesis primer1:
5'  CGTATCAGTGTGGCCAGAGATCTCTACCAGCAGACC  3'
D Mutagenesis primer 2:
5'  GGTCTGCTGGTAGAGATCTCTGGCCACACTGATACG  3'
Fig. 9 PCR primers for the mutation A843D in hamster SUR1. A = adenine, C = cytosine,
G = guanine, T = thymine; mutated bases are underlined.
Fig. 10 Separation of the PCR products of mutant (M1-M4) and wild type SUR1 treated
with Bgl II (see 3.3.3). The treated DNA was separated on an agarose gel against a length
standard (LS). The gel was stained by ethidium bromide and evaluated on an UV-
transilluminator at 312 nm. Mutant M1 was separated into four bands, therefore it was
neglected. Mutants M2 and M4 were separated into three fragments of 5253, 1301 and 1250
bp in length (the bands at 1301 and 1250 bp overlap), whereas the wild type was separated
into two fragments of 6554 and 1250 bp in length. One of the correct mutants (M4) was
chosen for plasmid preparation (see 3.3.4).
1250 bp
5253 bp
6554 bp
wild type
LS
1301 + 1250 bp
M1 M2 M3 M4
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4.2. Functional consequences of point mutations in SUR1 known to induce PHHI
The SUR1 gene consists of 39 exons and 38 introns. Up to now more than 40 mutations in
SUR1 are known to induce PHHI (THOMAS et al., 1995 and 1996; NICHOLAS et al., 1996;
NESTOROWICZ et al., 1997 and 1998, OTONKOSKI et al., 1999 and SHARMA et al. 2000).
Several of these known PHHI-inducing mutations are either insertions or deletions or reside in
introns resulting in splice-site or frame shift or nonsense triplets, which lead to truncated
proteins with complete loss of KATP channel activity (Fig. 11).
In this work the functional consequences of 24 point mutations residing in exons (22 PHHI-
inducing mutations and 2 polymorphisms) were analyzed. While 12 of these mutations
cumulate in NBF2, the rest distributes all over the protein with one mutation in NBF1 (Fig.
11). The mutations were introduced into SUR 1 (see 3.2.2) and the mutant proteins were
tested for high affinity [3H]glibenclamide binding, the inhibitory effect of ATP on
[3H]glibenclamide binding and for diazoxide binding.
Fig. 11 Scheme of the SUR1 gene. The gene consists of 39 exons represented by filled boxes,
and 38 introns represented by the lines connecting the boxes. The scheme illustrates the
position of 37 mutations known to induce PHHI and two polymorphisms (R74Q and N188S).
24 mutations residing in exons (in boxes) were introduced into SUR 1 and were functionally
analyzed.
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Fig. 12 Dissociation constants and
Bmax values for binding of gliben-
clamide to wild type and mutant SUR1
isoforms. [3H]glibenclamide (0.3 nM)
displacement assays were done with
membranes from COS7 cells expressing
wild type or mutant hamster SUR1. All
incubations were performed in tris-
buffer (50 mM; pH 7.4) containing 0.3
nM  [3H]glibenclamide and increasing
concentrations of non labelled
glibenclamide. Incubations were started
by addition of COS membranes (about
5µg/ml protein end concentration) and
terminated by filtration after 60
minutes. Non specific binding was
determined in parallel incubations with
0.1 µM non labelled glibenclamide and
specific binding was calculated by
subtraction of non specific from total
binding, The dissociation constants
(KDs) were calculated according to
CHENG and PRUSOFF (1973). The
number of sulfonylurea receptors (Bmax)
was calculated from displacement of
[³H]glibenclamide by non-labeled
glibenclamide (see 3.9.6.) (DEBLASI et
al., 1989). Results are shown as mean (±
SEM for KD values) from 4 to 6
independent displacement curves.
4.2.1. Analysis of high affinity [3H]glibenclamide binding
Nine of the constructs (V187D, R248X, R837X, Q954X, R1215Q, G1379R, G1382S,
R1394H and R1421C) did not show any high affinity [3H]glibenclamide binding, suggesting
that the mutations did either induce truncation or incorrect folding of the protein. For those 15
remaining mutations showing high affinity binding of [3H]glibenclamide KD values and
number of binding sites were determined. None of the mutations exerted a significant effect
on the KD or a clear effect on the expression rates, which means that all Bmax values lay within
the range defined by the 5% and 95% quartil, which was observed for the expression of wild
type SUR1 (Fig. 12).
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4.2.2. PHHI mutations with complete loss of diazoxide binding
Diazoxide is a potent activator of SUR1/KIR6.2 channels and it has been shown previously
that diazoxide binding to SUR1 can be measured indirectly by displacement of high affinity
[³H]glibenclamide binding (SCHWANSTECHER et al., 1998). Using that assay (see 3.7.3) four
of the mutations (R1494W, R1419C, L1544P, R1437Q) with preserved high affinity
glibenclamide binding, were found to completely abolish diazoxide binding (p < 0.01, n = 4–
6; Fig. 13). Interestingly, the mutations did also lead either to an abolishment or a strong
reduction of the inhibitory effect of 100 µM MgATP on high affinity [³H]glibenclamide
binding (p < 0.01, n = 4–6; Fig. 13). Notably, three (R1494W, R1419C, R1437Q) of these
four mutations reside in NBF2 (Fig. 11).
Fig. 13 PHHI- mutations with complete loss of diazoxide binding. Binding assays were
carried out with membranes from COS7 cells expressing wild-type or mutant hamster SUR1.
The incubation medium contained 0.3 nM [³H]glibenclamide, 280 µM diazoxide, 100 µM
MgATP and 1mM free Mg2+. Incubation was started by addition of membranes (final protein
concentration 5-50 µg/ml) and terminated by fitration after 60 minutes. Diazoxide binding
(%) is the percentage of ATP–dependent displacement of [³H]glibenclamide by 280 µM
diazoxide as defined in “Material and methods” (3.9.5). ATP induced inhibition (%) is the
percentage of displacement of [³H]glibenclamide by 100 µM MgATP as defined in “Material
and methods” (3.9.6). Non-specific binding was determined by parallel incubation sets which
contained 100 nM non-labeled glibenclamide and amounted to 5 ± 1% of total binding.
Results are presented as mean ± SEM for n = 4-6 independent experiments with independent
membrane preparations. For further details see (3.7.).
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4.2.3. PHHI-mutations with partial loss of diazoxide binding
Nine of the mutations (F591L, S1387F, R1353P, A116P, L508P, G1479R, C418R, N406D
and V1360M), however, did not completely abolish but significantly weakened diazoxide
binding and again the effects were paralleled by significant reductions of the inhibitory effect
of MgATP on glibenclamide binding (p < 0.01 or p < 0.05 and n = 4-6 each; Fig. 14).
Mutations inducing partial loss of diazoxide binding were distributed all over the protein,
residing either in transmembrane domains, like A116P, intracellular loops, like C418R or
NBF2, which for example is true for S1387F.
Fig.14 PHHI-mutations with partial loss of diazoxide binding. Results are presented as
mean ± SEM for n = 4-6 independent experiments with independent membrane preparations.
¬¬p < 0.01 or ¬p < 0.05 for comparison with the wild type. For further details see Fig. 13.
4.2.4. Mutations that do not affect diazoxide binding
To analyze whether loss of potassium channel opener binding is a general phenomenon of
point mutations in SUR1, R74Q and N188S were tested which presumably represent
polymorphisms without functional relevance. In addition to that random mutations were
chosen as controls. As shown in Fig. 15, indeed none of these mutations showed a significant
reduction of either diazoxide binding or ATP-induced inhibition of glibenclamide binding
(p > 0.35, n = 4-6 each).
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Fig. 15 Mutations that do not affect diazoxide. Results are presented as mean ± SEM for n =
4-6 independent experiments with independent membrane preparations. For further details see
Fig. 13.
4.2.5. Correlation of diazoxide binding with the effect of ATP on glibenclamide binding
The effect of all mutations on ATP-induced inhibition of glibenclamide binding and on
diazoxide binding was strikingly parallel evidenced by the fact that the square of diazoxide
binding showed a strong linear correlation with the effect of ATP on glibenclamide binding
(Fig. 16, correlation coefficient = 0.94, p < 0.0001).
 diazoxide binding
 ATP-induced inhibition
of [3H]glibenclamide binding
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Fig. 16 Loss of diazoxide binding correlates with the inhibitory effect of ATP on
glibenclamide binding.
4.3. Homology modeling of the nucleotide binding folds in SUR1
4.3.1 Comparison between the sequences of HisP and the NBFs of SUR1
The recent report of the high resolution crystal structure of HisP, the NBF subunit of the
histidine permease complex of Salmonella typhimurium (HUNG et al., 1998), represents a
significant breakthrough towards the elucidation of the mechanism of solute translocation by
ABC transporters. It was therefore of great interest to find out whether the tertiary structure of
the NBFs of SUR1 can be deduced from these data.
Sequence alignment revealed a high degree of homology between HisP and the NBFs
of SUR1 with especially strong conservation within the characteristic motifs, i.e. the Walker
A and B motifs and the so-called linker region. Particularly, the identical sequence of b-sheets
and a-helices (with a total of 12 b-sheets and 9 a-helix-elements in each of the three proteins)
pointed at very similar tertiary structures (Fig. 17).
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4.3.2 Analogous model for the tertiary structure of NBF1 and NBF2 of SUR1
Based on the data obtained from the crystal structure of HisP and the sequence alignment
described above, a model for the tertiary structure of both NBFs of SURs was deduced. In this
model, the structure of either NBF1 or NBF2 is that of an “L” with two thick arms (arm I and
arm II); the ATP binding pocket is near the end of arm I (Fig. 18).
Fig. 18 Analogous molecular modeling of the NBFs of SUR1. View of the NBFs along an
axis perpendicular to their two fold axis. The program BRAGI (SCHOMBURG and REICHELT,
1988) was used for sequence exchange and the program O (JONES, 1985) for visualisation.
The pictures were drawn using MOLSCRIPT (KRAULIS, 1991) and rendered using gl_render
(ESSER L, unpublished) and POV-RaY™. As structural template the coordinates of the ATP-
binding-subunit of the histidine permease from Salmonella typhimurium (Brookhaven Protein
Databank, code 1bOu) were used.
NBF1 NBF2
A
R
M
 I
I
ARM I
ATP binding
pocket
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In analogy to Fig. 2 in the article of HUNG et al. (1998) a diagram of the secondary structure
of the NBFs of SUR1 is presented in Fig 19. A six-stranded b-sheet (b3 and b8-b12) spans
both arms of the L, with a domain of a a plus b-type structure (b1, b2, b4-b6 and a1) on one
side (within arm I) and a domain of mostly a helices (a3-a9) on the other side (within arm II)
of the sheet.
Fig 19 Diagram of the secondary
structure of the NBFs of SUR1 in
analogy to Fig. 2 in the article of
HUNG et al., (1998). Cylinders and
arrows represent a-helices and b-
sheets, respectively. ATP is shown in
black (A, adenine; R, ribose; P,
phosphate group).
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4.3.2.1. Interaction of NBF2 with ATP
Figure 20 shows amino acids within NBF2 which were predicted by the model to be critical
for ATP-binding. Actually, the tyrosine in position 1354 at the end of b1 (corresponding to
Y16 in HisP) stabilizes the orientation of ATP by way of hydrophobic interactions between
the aromatic ring (of tyrosine) and the adenine base (of ATP). The histidine residue
(corresponding to H211 in HisP) in the 10th b-sheet supports the orientation of the g-phosphate
via hydrogen bonding. Glutamine 1427 (corresponding to Q100 in HisP) between the 8th b-
sheet and the 3rd a-helix as well as glutamic acid 1507 (corresponding to E179 in HisP) in the
9th b-sheet form hydrogen bonds with a water molecule, which interacts with the g-phosphate
of ATP and presumably is of central importance for hydrolysis. Of particular importance also
is the aspartate in position 1506 (corresponding to D178 in HisP) at the end of the Walker B
motif, which most likely stabilizes the magnesium ion during the hydrolytic cycle (Fig. 20
and 21A).
Fig. 20 Conserved amino acids with key importance for ATP-binding to NBF2. For further
details see Fig. 18.
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To test the functional relevance of these residues point mutations were performed.
Corresponding mutations in HisP had been shown to induce partial or complete inhibition of
ATPase activity (HUNG et al.,1998).
In accordance with the findings for HisP, substitution of the adenine-ring stabilizing
tyrosine in position 1354 by serine led to a complete inhibition of ATP-induced diazoxide
binding to SUR1 (Fig. 21). Similarly, complete inhibition of diazoxide binding was observed
for substitution of the lysine residue in the Walker A motif (K1385R; see Fig. 21 and Fig. 23).
On the basis of the expected model, this residue is of central importance for the coordination
of the b-phosphate. Furthermore, substitution of aspartate 1506 (D1506N) as well as
substitution of residues involved in coordination of the g-phosphate through water molecules
(Q1427L, E1507K, H1541D) led to partial inhibition of diazoxide binding. This partial
inhibition became complete when the substitutions in positions 1427 and 1507 were combined
(Fig 21 A and B). Both findings are in good agreement with the predictions made by the
model.
4.3.2.2. Interaction of NBF1 with ATP
Similar studies in NBF1 led to somewhat different results. Thus, substitution of the
phenylalanine in position 685 (Fig. 22 A) by serine did not have an effect on diazoxide
binding, whereas all other substitutions (K719R, D854N, Q775L, D855A and H889D) led to
almost complete inhibition of binding.
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Fig. 21 Interaction of NBF2
of SUR1 with ATP. (A)
Atomic details of the putative
interaction of NBF2 of SUR1
(residues are boxed) with
ATP (centre). Only hydrogen
bonds and aromatic stacking
are shown, by dashed lines
and vertical lines, respect-
ively. The residues investi-
gated (Y1354, K1385,
Q1427, D1506, E1507 and
H1541) are indicated by
black boxes.
(B) Effect of point mutations
in NBF2 on diazoxide
binding to SUR1. Binding
assays were carried out with
membranes from COS7-cells
expressing wild type (wt) or
mutant SUR1. Mean values ±
SEM from n = 5-6 indepen-
dent experiments are given.
For further details see Fig.
13.
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Fig. 22 Interaction of NBF1 of SUR1
with ATP. (A) For further details see
Fig 21.
(B) Effect of point mutations in
NBF1 on diazoxide binding to
SUR1. Binding assays were
carried out with membranes
from COS7-cells expressing
wild type (wt) or mutant SUR1.
Mean values ± SEM from n = 5-
6 independent ex-periments are
given. For further details see
Fig. 13.
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4.3.2.3. PHHI mutations in NBF2
Various point mutations in NBF2 of SUR1 cause PHHI (see 4.2). Some of them induce a
complete loss of high affinity glibenclamide binding, indicating incorrect folding or
expression of the protein (see 4.2.1). In others glibenclamide binding is unchanged. However,
the latter mutations lead to either an abolishment or a strong reduction of diazoxide binding,
indicating that the residues occupy functionally critical positions in NBF2. To verify this
hypothesis, the position of PHHI mutations in the presumed tertiary structure of NBF2 of
SUR1 was determined. (Fig. 23; for discussion of the results see 5.2)
Fig. 23 PHHI mutations in NBF2. K1385R and D1506N are highly conserved residues in
the Walker A and B motifs, respectively. For further details see Fig. 18.
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5. Discussion
5.1. Loss of KCO-binding is indicative for PHHI
SURs are members of the ATP-binding cassette (ABC) superfamily with two folds (NBFs)
for binding and hydrolysis of nucleotides (AGUILAR-BRYAN et al., 1995 and 1998; INAGAKI et
al., 1995). These folds have the Walker A and B motifs and a connecting linker region
(AGUILAR-BRYAN et al., 1998; HIGGINS, 1992). The Walker A motif, -gly-x-x-gly-x-gly-lys-
(ser/thr)-, forms part of the nucleotide-binding pocket, with the conserved lysine interacting
with the b- and g-phosphates of ATP (SARASTE et al., 1990; HIGGINS, 1992). Mutation of this
residue significantly reduces or abolishes hydrolytic activity in other ATPases (e.g. P-
glycoprotein). The linker region with the consensus motif, -leu-ser-gly-gly-gln-, is thought to
be involved in transducing conformational changes resulting from ATP hydrolysis (AMES et
al., 1992).
Mutation of the highly conserved Walker A lysine (K719R or K1385R in SUR1,
K711R or K1352R in SUR2B) in either nucleotide binding fold of SUR1 or SUR2B
eliminated ATP activation of KCO binding, while binding was weakened, but not abolished
by mutations in the linker regions (e.g. G827D or G1479R in SUR1, G809D or G1446R in
SUR2B) (SCHWANSTECHER et al., 1998; SCHWANSTECHER, 1998). There was a strong
correlation between KCO binding and the activation of mutant SUR1/ or SUR2B/wildtype
KIR6.2 channels which established that the KCO binding sites on SURs are functionally
relevant receptor sites. Mutants without binding activity were not activated by KCOs, while
G827D or G1479R in SUR1 and G809D or G1446R in SUR2B showed both impaired KCO
binding and KCO activation (SCHWANSTECHER et al., 1998; SCHWANSTECHER, 1998).
The authors therefore concluded that binding and most probably hydrolysis of ATP in
both NBFs induce a conformational change, which strongly increases KCO affinity
(SCHWANSTECHER et al., 1998; SCHWANSTECHER, 1998). Amazingly, parallel effects on
channel activation by the nucleoside diphosphates ADP and GDP were observed (GRIBBLE et
al., 1997, SHYNG et al., 1998, SIEVERDING, 1998b; SCHWANSTECHER, 1998), suggesting that
the binding sites for KCOs and nucleoside diphosphates might be controlled by the same
ATP-dependent mechanism (SIEVERDING, 1998b; SCHWANSTECHER et al., 1998).
Sulfonylurea receptors thus might function as molecular switches (see Fig. 24;
SIEVERDING, 1998b; SCHWANSTECHER et al., 1998; SCHWANSTECHER, 1998) - similar to
regulatory GTPases (e.g. Ras or EF-Tu; WITTINGHOFER and PAI, 1991, ABEL et al., 1996). In
the absence of ATP the receptor is in its insensitive "off conformation" which cannot be
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activated by KCOs and NDPs. Hydrolysis of ATP in both NBFs could induce a sensitive
conformational state, the "on conformation", which allows interaction of KCOs and NDPs
with their receptor sites. Mutations in the NBFs prevent switching, lock the receptor in its
"off-conformation" and thus prevent physiological regulation of channel activity by changes
in the cytosolic concentrations of nucleoside diphosphates.
Fig. 24 Sulfonylurea receptors might function as molecular switches. In the absence of ATP
the receptors are in their insensitive "off conformation" which cannot be activated by KCOs
and NDPs. Binding and presumably hydrolysis of ATP in both NBFs induces a
conformational change ("on conformation") which allows interaction of KCOs and NDPs
with their receptor sites. The "on conformation" induces a slight decrease in sulfonylurea
affinity (Figure according to SIEVERDING, 1998b).
High affinity binding of glibenclamide to SUR1 does not require the "on conformation".
Indeed, quite the reverse is true as micromolar concentrations of MgATP induce a reduction
of high affinity glibenclamide binding (SCHWANSTECHER et al., 1990, 1991; SIEVERDING,
1998a). A more detailed analysis of the mechanism of ATP-induced inhibition of
glibenclamide binding revealed that MgATP did not alter the number of binding sites but
slightly reduced glibenclamide affinity by an allosteric interaction (SIEVERDING, 1998a).
‘‘on“
ATPATP
KCOs
SU
NDPs
Mutations in SUR1 induce PHHI by locking 
the receptor in its "off" conformation
"off " "on"
SU
“off“
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In summary, the "on conformation" of the sulfonylurea receptor is characterized not
only by a high affinity for KCOs but also by a slightly reduced affinity for sulfonylureas. The
"switch model" thus predicts that a loss of KCO-binding paralleled by a loss of an inhibitory
effect of MgATP on glibenclamide binding is indicative for a defect in the switch mechanism.
Parallel loss of nucleoside diphosphate sensitivity would consequently lead to an inabilitiy of
the channel to increase open probability when blood glucose is lowered resulting in
hyperinsulinemia and hypoglycemia.
To test this hypothesis 22 mutations in SUR1 known to cause PHHI were functionally
analyzed. Nine of the constructs (V187D, R248X, R837X, Q954X, R1215Q, G1379R,
G1382S, R1394H and R1421C) did not show any high affinity glibenclamide binding (Fig.
25) suggesting that the mutations did either induce truncation or incorrect folding of the
protein resulting in a complete loss of channel activity. Consistently, it was shown previously
that V187D, which is the most common PHHI-inducing mutation in the Finnish population,
and R1394H did not express measurable KATP-channel activity (OTONKOSKI et al., 1999;
SHYNG et al., 1998).
Functional studies have not been performed for R248X, R837X and Q954X, so far.
However, as these three point mutations result in the introduction of a termination codon, the
SUR1 proteins encoded by the mutant alleles would be predicted to lack essential parts (see
Fig. 24). Thus loss of binding in these mutants is most probably due to the fact that the
truncated SURs are unable to form functional channels when coexpressed with KIR6.2.
G1379 and G1382 represent the first and second glycine residue of the Walker A motif
in NBF2. Both residues are strictly conserved between eucaryotic ABC proteins and
substantial evidence exists for the importance of these residues in the structure and function of
other members of the ABC superfamily. Consistent with our observation of a complete lack of
glibenclamide binding replacement of the corresponding glycine residues in F1ATPase or
histidine permease resulted in either non-functional or dysfunctional molecules (SHEN et al.,
1994; SHYAMALA et al., 1991).
While we did not see glibenclamide binding in the R1215Q, G1382S and R1421C
(which corresponds to R1420C in human SUR1) mutants, they have been shown by others to
generate active channels when coexpressed with KIR6.2, albeit the mean current amplitudes
were reduced by 40 - 60 % indicating lower expression of the mutant channels (SHYNG et al,
1998, MATSUO et al., 2000). At this stage of our investigations the reason for this discrepancy
is unclear.
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From the PHHI mutations with preserved high affinity glibenclamide binding four led
to a complete abolishment and nine (e.g. F591L, G1479R) to a significant reduction in
diazoxide binding (Fig. 14). Consistently, - in other studies - F591L and G1479R were found
to induce a substantial impairment of channel activation by diazoxide and nucleoside
diphosphates (SHYNG et al., 1998; SCHWANSTECHER et al., 1998; SCHWANSTECHER, 1998).
Neither polymorphisms like R74Q or N188S nor random mutations showed a decrease
of diazoxide binding or ATP-induced inhibition of glibenclamide binding (Fig. 15). These
findings are consistent with patch clamp studies demonstrating that N188S does not alter the
sensitivity of the KATP channel to nucleoside diphosphates or diazoxide (DUNNE, 1997; SHYNG
et al., 1998).
The effects of all mutations on diazoxide binding and ATP-induced inhibition of
glibenclamide binding were strictly correlated (Fig. 16). In conclusion, the results from this
study strongly support the idea that locking the receptor in its non-binding state induces PHHI
via preventing KATP channel activation by physiological activators, specifically MgADP.
Fig. 25 Putative transmembrane topology of SUR1 as predicted by Tusnady et al., 1997.
Positions of PHHI-associated mutations are indicated. V187D, R248X, R837X, Q954X,
R1215Q, G1379R, G1382S, R1394H and R1421C did not show any high affinity
glibenclamide binding. From the PHHI mutations with preserved high affinity glibenclamide
binding four led to a complete abolishment (R1419C, R1437Q, R1494W and L1544P) and
nine (A116P, N406D, C418R, L508P, F591L, R1353P, V1360M, S1387F and G1479R) to a
significant reduction in diazoxide binding. R74Q and N188S are polymorphisms.
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Interestingly, PHHI mutations resulting in loss of potassium channel opener binding
were not only localized in NBF1 or NBF2 but also in areas outside the nucleotide binding
folds, particularly in transmembrane domains 3, 8, 9 and 11 and the intracellular loops 4 and
8, suggesting that these regions are involved in the switching process.
5.2 The tertiary structure of the NBFs of SURs closely resembles that of HisP
Recently, the three-dimensional crystal structure of HisP, the ATP binding subunit of the
histidine permease, has been elucidated (HUNG et al., 1998; see 4.3). Sequence alignment of
HisP with the NBFs of SUR1 revealed a high degree of homology and suggested very similar
tertiary structures. Based on this alignment and the data from the crystal structure, a tertiary
structure of the NBFs of SURs was deduced and the functional relevance of residues
predicted to be critical for ATP binding was examined.
Indeed, substitution of highly conserved amino acids in both NBFs involved in
stabilizing the orientation of ATP by interacting directly with the b-phosphate (K719 in
NBF1, K1385 in NBF2), or indirectly via Mg2+ (D854 in NBF1, D1506 in NBF2) or
hydrogen bonding with the g-phosphate (Q775, D855, H889 and V715 in NBF1; Q1427,
E1507, H1541 in NBF2) induced a partial or complete loss of diazoxide binding (Fig. 21 and
22). In HisP mutation of the corresponding residues is known to significantly reduce or
abolish ATPase activity (SHYAMALA et al., 1991).
Upstream of the Walker A motif of most ABC transporters a conserved aromatic amino
acid is found (CROOP , 1998; SCHNEIDER and HUNKE, 1998). The crystal structure of HisP
implicates this residue (Y16 in HisP) as a critical binding contact for the adenine ring of ATP
and consistently, substitution of tyrosine16 by serine abolished the ability of HisP to bind
ATP and consequently disrupted transport (SHYAMALA et al., 1991). In SUR1, Y16
corresponds to tyrosine 1354 in NBF2 and phenylalanine 685 in NBF1. While substitution of
Y1354 by serine induced a complete inhibition of diazoxide binding, replacement of
phenylalanine 685 was without effect. The failure of F685S to influence diazoxide binding
could be due to the fact that this residue is not important for the coordination of the adenine
ring in NBF1. However, it is also conceivable that the decrease in ATP-affinity induced by
the substitution is not sufficient to reduce diazoxide binding in the presence of 100 µM ATP.
This would e.g. be the case if  NBF1 had a much higher affinity for ATP than NBF2.
Consistent with the latter explanation, a large difference in the affinities of NBF1 and NBF2
has been proposed for CFTR (SENIOR and GADSBY, 1997).
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5.3 The tertiary structure of NBF2 in SUR1 predicts the functional consequences of
PHHI mutations
Based on our results presented above we would predict various point mutations in NBF2 of
SUR1 to cause PHHI by locking the receptor in its "off conformation". Among these R1419C,
R1437Q and R1494W led to a complete abolishment and R1353W, S1387F and G1479R to a
partial reduction of diazoxide binding (see 5.1). To propose a functional basis for these
defects, the mutated residues were localized in the putative tertiary structure of the NBFs of
SUR1 (see Fig. 23).
Arginine 1353 presumably stabilizes tyrosine 1354 which is critical for the coordination
of the adenine ring of ATP (see 5.2). While glutamate 1507 interacts with the g-phosphate
(see 5.2), serine 1387 most probably stabilizes the a-phosphate of ATP as well as tyrosine
1354 via hydrogen bonding (see Fig. 21 and Fig. 23).
R1419 should be part of a short loop connecting the sixth to the eight b-sheet and thus
might be crucial for the conformation of this region which is involved in spanning arm I and
arm II (see Fig. 19). R1437 and G1479 are found in a short stretch in front of helical
structures (a3 und a5, respectively) forming part of the linker region. Presumably, the
orientation of this region is altered by substitution of these amino acids. Moreover, R1494
within the fifth a-helix is part of the linker region which is thought to be involved in
transducing conformational changes resulting from ATP hydrolysis (AMES et al., 1992).
Indeed, the linker region forms a substantial part of arm II (see Fig. 19 and 23) which in HisP
is essential for the interaction between the nucleotide binding folds and transmembrane
domains (HUNG et al. 1998).
In conclusion, evidence is presented that the tertiary structure of the NBFs of SURs
closely resembles that of HisP and allows to predict the functional consequences of mutations
leading to a dysregulation of insulin secretion.
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6. Summary
Persistent hyperinsulinemic hypoglycemia of infancy (PHHI), is a disorder of insulin
secretion with strong hyperinsulinemia despite severe reduction of blood glucose. At present
all defects known to cause this disease finally result in a reduced open probability of the KATP
channel in the plasma membrane of the pancreatic b-cell, thus inducing deregulated
membrane depolarisation, opening of L-type Ca2+-channels and insulin secretion triggered by
persistently elevated cytosolic Ca2+-levels.
In rare familial cases PHHI is induced by point mutations in the glucokinase or
glutamate dehydrogenase gene resulting in either increased affinity for glucose or reduced
allosteric inhibition by GTP. Both types of defects lead to an elevation of the cytosolic
ATP/ADP ratio with subsequent inhibition of KATP channel activity. Defects in the KATP
channel itself, however, seem to be a much more common cause for the syndrome and up to
now more than 40 mutations in SUR1 are known to induce PHHI. Some of these mutations
are either insertions or deletions or reside in introns resulting in splice- site or frame shifts or
nonsense triplets, which lead to truncated proteins with complete loss of KATP channel
activity. Others, however, induce a reduction of the response to stimulation by MgADP.
Recently, it was speculated that ATP hydrolysis in both nucleotide binding folds
switches sulfonylurea receptors (the regulatory subunits of KATP channels) from an „off“ into
an „on“ conformation, which besides high affinity for potassium channel openers and
nucleoside diphosphates is characterised by a slightly reduced affinity for sulfonylureas. In
this model PHHI results from locking the receptor in its „off“-conformation, which should
result in loss of KCO binding and lack of an inhibitory effect of MgATP on glibenclamide
binding.
To test this hypothesis 22 mutations in SUR1 known to cause PHHI were functionally
analyzed. Nine of the constructs did not show any high affinity glibenclamide binding
suggesting that the mutations did either induce truncation or incorrect folding of the protein
resulting in a complete loss of channel activity. Among the mutations with preserved high
affinity binding of [3H]glibenclamide four were found to completely abolish and nine to
significantly weaken diazoxide binding. Interestingly, the mutations did also lead to either an
abolishment or a strong reduction of the inhibitory effect of 100 µM MgATP on high affinity
[3H]glibenclamide binding. Indeed, the effects of all mutations on these parameters were
strikingly parallel evidenced by the fact that the square of diazoxide binding showed a strong
linear correlation with the effect of ATP on glibenclamide binding
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These findings thus convincingly support the idea that locking the receptor in its non-
binding state induces PHHI via preventing KATP channel activation by physiological
activators, specifically MgADP.
Interestingly, PHHI mutations resulting in loss of potassium channel opener binding
were not only localized in NBF1 or NBF2 but also in areas outside the nucleotide binding
folds, particularly in transmembrane domains 3, 8, 9 and 11 and the intracellular loops 4 and
8, suggesting that these regions are involved in the switching process.
Recently, the three-dimensional crystal structure of HisP, the ATP binding subunit of
the histidine permease, has been elucidated. Sequence alignment of HisP with the NBFs of
SUR1 revealed a high degree of homology and suggested very similar tertiary structures.
Based on this alignment and the data from the crystal structure, a tertiary structure of the
NBFs of SURs was deduced and the functional relevance of residues predicted to be critical
for ATP binding and/or hydrolysis was examined. As expected, substitution of highly
conserved amino acids in both NBFs involved in stabilizing the orientation of ATP by
interacting directly with the b-phosphate or indirectly via Mg2+ or hydrogen bonding with the
g-phosphate induced a partial or complete loss of diazoxide binding.
To propose a structural basis for the defects of PHHI mutants inducing partial or
complete loss of diazoxide binding, the location of several PHHI mutations in the tertiary
structure was determined. The results suggest that some of the PHHI mutants (e.g. R1353P or
S1387F) are critical for the coordination of ATP, while others (e.g. R1437Q, G1479R) are
essential for transducing conformational changes resulting from ATP hydrolysis.
Thus in this last part of the thesis, evidence is presented that the tertiary structure of the
NBFs of SURs closely resembles that of HisP and allows a predicition of the functional
consequences of mutations leading to a dysregulation of insulin secretion.
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